|
AU2015201475A1
|
|
Compounds, compositions, processes of making, and methods of use related to inhibiting macrophage migration inhibitory factor
|
|
AU2012205248A1
|
|
Guanylhydrazone salts, compositions, processes of making and methods of using
|
|
AU2012201680A1
|
|
Compounds, compositions, processes of making, and methods of use related to inhibiting macrophage migration inhibitory factor
|
|
WO2011091040A1
|
|
Use of isoxazoline compounds and compositions in bladder cancer
|
|
WO2011066484A2
|
|
Isoxazoline compounds in type 2 diabetes and other maladies
|
|
WO2011066482A2
|
|
Chiral synthesis of isoxazolines, isoxazoline compounds, and uses thereof
|
|
WO2010077734A2
|
|
Novel antiviral compounds, compositions, and methods of use
|
|
WO2010077740A2
|
|
Novel antiviral compounds, compositions, and methods of use
|
|
BRPI0918468A2
|
|
poi prevention
|
|
US2009036540A1
|
|
Guanylhydrazones in Methods of Treatment or Diagnosis as Modulators of Signal Transduction
|
|
US2008096909A1
|
|
Apomorphine inhibitors of amyloid-beta (abeta) fibril formation and their use in amyloidosis based disease
|
|
US2007282005A1
|
|
Protective role of semapimod in necrotizing enterocolitis
|
|
US2006014833A1
|
|
Guanylhydrazone salts, compositions, processes of making and methods of using
|
|
BRPI0507818A
|
|
compound and inhibition methods
|
|
CA2559507A1
|
|
Compounds, compositions and methods for inhibiting or treating hiv-1
|
|
WO2005020902A2
|
|
Compositions and methods for treating and diagnosing irritable bowel syndrome
|
|
AU2002357911A8
|
|
Apomorphine inhibitors of amyloid-beta (abeta) fibril formation and their use in amyloidosis based disease
|
|
US7205107B2
|
|
Macrophage migration inhibitory factor (MIF) promoter polymorphism in inflammatory disease
|
|
EP1411930A2
|
|
Isoxazoline compounds having mif antagonist activity
|
|
EP1404180A2
|
|
Peripheral blood fibrocytes differentiation pathway and migration to wound sites
|
